Neurocrine appoints Samir Siddhanti as chief business officer

Reuters2026/07/21 20:05

By:Reuters

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Neurocrine Biosciences appointed Samir Siddhanti chief business officer, adding him to the executive Management Committee.
He will lead enterprise growth strategy, covering business development, corporate strategy, alliance management, program management.
Siddhanti joined Neurocrine in 2017, most recently vice president of business development, leading transactions including the $2.9 billion Soleno Therapeutics acquisition.
He previously worked in biotechnology equity research at Goldman Sachs.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurocrine Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607211605PR_NEWS_USPR_____LA09012) on July 21, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Neurocrine appoints Samir Siddhanti as chief business officer

You may also like

Crypto prices